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Summary
 
CD40 activates nuclear factor kappa B (NF
 
k
 
B) and the mitogen-activated protein kinase
(MAPK) subfamily, including extracellular signal–regulated kinase (ERK). The CD40 cyto-
plasmic tail interacts with tumor necrosis factor receptor–associated factor (TRAF)2, TRAF3,
TRAF5, and TRAF6. These TRAF proteins, with the exception of TRAF3, are required for
NF
 
k
 
B activation. Here we report that transient expression of TRAF6 stimulated both ERK
and NF
 
k
 
B activity in the 293 cell line. Coexpression of the dominant-negative H-Ras did not
affect TRAF6-mediated ERK activity, suggesting that TRAF6 may activate ERK along a Ras-
independent pathway. The deletion mutant of TRAF6 lacking the NH
 
2
 
-terminal domain
acted as a dominant-negative mutant to suppress ERK activation by full-length CD40 and sup-
press prominently ERK activation by a deletion mutant of CD40 only containing the binding
site for TRAF6 in the cytoplasmic tail (CD40
 
D
 
246). Transient expression of the dominant-
negative H-Ras significantly suppressed ERK activation by full-length CD40, but marginally
suppressed ERK activation by CD40
 
D
 
246, compatible with the possibility that TRAF6 is a
major transducer of ERK activation by CD40
 
D
 
246, whose activity is mediated by a Ras-inde-
pendent pathway. These results suggest that CD40 activates ERK by both a Ras-dependent
pathway and a Ras-independent pathway in which TRAF6 could be involved.
 
C
 
D40 is a cell-surface glycoprotein on B lymphocytes,
dendritic cells, follicular dendritic cells, and thymic
epithelial cells (1), and a member of the TNF-
 
a
 
 receptor
superfamily that includes 55- and 75-kD TNF receptors
(TNFR1 and TNFR2, respectively), CD30 receptor, low-
affinity nerve growth factor receptor, lymphotoxin 
 
b
 
 re-
ceptor (LT
 
b
 
R), and Fas antigen (1).
The cytoplasmic domain of the TNFR superfamily
members lacks sequences indicative of catalytic activity, but
is associated with a signal transducer, TNFR-associated fac-
tor (TRAF; reference 2). The cytoplasmic domain of hu-
man CD40 consists of 62 amino acids at positions 196–257
and is associated with TRAF2, TRAF3, TRAF5, and
TRAF6 (3–9) and Janus kinase (Jak)3 (10); the membrane
proximal region of the cytoplasmic tail of CD40 contains a
proline-rich region at positions 202–209 that is crucial for
Jak3 binding (10). TRAF6 binds to the NH
 
2
 
-terminal cy-
toplasmic tail of CD40 at positions 210–225, although the
possibility can not be excluded that full association of
TRAF6 with CD40 may also require the COOH-terminal
part at positions 226–249 (9). TRAF2, TRAF3, and TRAF5
bind to the COOH-terminal CD40 cytoplasmic domain at
positions 226–249 (9), containing a minimum element,
designated TIMct, responsible for TRAF2 and TRAF3
 
1
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2
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2
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binding and signal transduction mediating nuclear factor
kappa B (NF
 
k
 
B) activation (7).
Stimulation of CD40 results in activation of protein ty-
rosine kinases (PTKs), NF
 
k
 
B, the mitogen-activated pro-
tein kinase (MAPK), and Jak3/signal transducers and acti-
vators of transcription (STAT)3 (10–18), and it mediates
critical biological effects in B cell growth, survival, and dif-
ferentiation (19–27). It is known that TRAF2 and TRAF5
play a role in NF
 
k
 
B activation in signaling through CD40, as
well as TNFR1, TNFR2, CD30, and lymphotoxin 
 
b
 
 re-
ceptor (6–8, 28–32). TRAF6 participates in NF
 
k
 
B activa-
tion signaled by CD40 and IL-1 receptor (9, 33). The
TRAF family is characterized by a homologous COOH-
terminal TRAF-COOH (TRAF-C) domain, an 
 
a
 
-helical
TRAF-NH
 
2
 
 (TRAF-N) domain, and an NH
 
2
 
-terminal
RING finger with the exception of TRAF1 (2–6, 8, 9, 30,
33). The effector function of TRAF2 and TRAF5 toward
NF
 
k
 
B activation is mediated by its NH
 
2
 
-terminal RING
finger domain (6, 8, 30), whereas that of TRAF6 is medi-
ated by the RING finger and zinc fingers (9, 33).
It has been reported that TRAF2 stimulates c-jun NH
 
2
 
-
terminal kinase (JNK) activity in TNFR1 signaling (34–36),
leading to the idea that TRAF2 may also play a role in JNK
activation by CD40 (15, 16). However, the signaling path-
way coupling CD40 to extracellular signal-regulated kinase
(ERK) activation has remained unknown. To investigate
which TRAF proteins might participate in ERK activation,
we have performed transient transfection experiments in
the human embryonic kidney 293 cell line. In the present
study, we demonstrate that TRAF6 plays a role as a signal
transducer in ERK activation by CD40, probably along a
Ras-independent pathway.
 
Materials and Methods
 
Cell Culture.
 
Human embryonic kidney cell line 293 was
maintained in DME supplemented with 10% FCS, 200 mM
 
l
 
-glutamine, and penicillin/streptomycin.
 
Plasmid Construction.
 
TRAF2, TRAF3, and human CD40
cDNA were obtained by the reverse transcription PCR (RT-PCR)
by use of messenger RNA purified from B cell lymphomas,
WEHI231 and Raji, with primers flanking the entire coding re-
gion, and then cloned into pMIKHygB, a gift from Dr. K.
Maruyama (Tokyo Medical and Dental University, Tokyo, Ja-
pan). Deletion mutants of TRAF2 that lack a RING finger motif
(amino acids [aa] 87–501) and the TRAF-C domain (aa 352–501)
were constructed by PCR. Isolation of TRAF5 and TRAF6 cDNAs
and construction of the expression vectors coding full-length
TRAF5, full-length TRAF6, and the TRAF-C of TRAF6 were
reported previously (9, 30). A deletion mutant of human CD40,
designated CD40
 
D
 
246, that removes 32 aa at positions 226–257
from the cytoplasmic tail was previously described (9). Domi-
nant-negative Raf-1 (aa 1–258) was constructed by reverse tran-
scription PCR, according to Schaap et al. (37). Dominant-negative
N17Ras (38) and glutathione-S-transferase (GST) fusion ERK2
(pGSTM1) were provided by Dr. G.M. Cooper (Dana-Farber
Cancer Institute, Harvard Medical School, Boston, MA) and Dr.
K. Takishima (National Defense Medical College, Saitama, Ja-
pan), respectively. Construction of a dominant-negative mutant of
MAPK/ERK-activating kinase (MEK)1, designated MEK1
 
DN
 
, and
a constitutively activated mutant of MEK1, designated MEK1
 
EE
 
,
was previously described (39). All cDNA fragments were sub-
cloned into pMIKHygB.
ERK-dependent activator and reporter constructs were pre-
pared according to Seth et al. (40, 41). In brief, the fusion of the
GAL4 DNA-binding domain and the nuclear localization signal
(aa 1–147) and NH
 
2
 
-terminal transcriptional activation region of
c-Myc (aa 2–103) were constructed in vector pGBT9 (Clontech,
Palo Alto, CA), and its HindIII-SalI fragment was digested and
subcloned into pMIKHygB, designated pGAL4MycN. A firefly
luciferase reporter containing two copies of the GAL4 binding site
adjacent to a thymidine kinase promoter was constructed into
pGL2 (Promega, Madison, WI), designated pGAL4tkLuc. A pre-
vious study by Seth et al. (41) showed that, in cotransfected cells
with the GAL4–c-Myc fusion construct and luciferase reporter,
the phosphorylation state of the NH
 
2
 
-terminal c-Myc transactiva-
tion domain was increased in an ERK-dependent manner, result-
ing in an increase in the activity of the luciferase reporter gene
(41). Therefore, this ERK-dependent activator and reporter sys-
tem allows one to monitor ERK activity by measuring the lu-
ciferase reporter activity. NF
 
k
 
B-dependent luciferase constructs
containing three copies of an NF
 
k
 
B binding site from immuno-
globlin 
 
k
 
 light chain enhancer and the thymidine kinase promoter
was constructed into pGL2, designed pkBtkLuc. All cDNAs and
constructs were confirmed by DNA sequencing.
 
In Vitro MAPK Assay.
 
An in vitro kinase assay for endoge-
nous ERK activity was performed as previously described (17).
For estimating exogenous ERK2 kinase activity, 293 cells were co-
transfected with 1 
 
m
 
g of GST-ERK2 and various amounts of plas-
mid constructs by the calcium phosphate coprecipitation method.
The total amount of DNA was adjusted with empty vector at 10 
 
m
 
g.
When 293 cells were cotransfected with 1 
 
m
 
g of CD40 cDNA,
the cells were stimulated with anti-CD40 mAb (2 
 
m
 
g/ml) 24 h
after transfection. In some experiments, cells were analyzed for
the expression of CD40 on the surface by FACScan
 
Ò
 
 (Becton Dick-
inson, Mountain View, CA) with FITC-conjugated anti–human
CD40 mAb (5C3; PharMingen, San Diego, CA). The cell lysates
were incubated with glutathione-coupled Sepharose 4B (Pharma-
cia, Uppsala, Sweden) at 4
 
8
 
C for 1 h. The Sepharose beads were
pelleted down by centrifugation and washed twice with lysis buf-
fer and with Tris-buffered saline (10 mM Tris-HCl, pH 7.2, 100
mM NaCl) supplemented with 5 mM benzamidine and 1 mM
Na
 
3
 
VO
 
4
 
. The GST-ERK2 immobilized on Sepharose was di-
rectly subjected to a kinase reaction as previously described (17).
 
Luciferase Assay.
 
Cells were cotransfected with either full-
length CD40 or CD40
 
D
 
246 and ERK-dependent activator and
reporter plasmids consisted of 500 ng of pGAL4tkLuc and 100 ng
of pGAL4MycN, or NF
 
k
 
B-dependent plasmid of 20 ng of pkBt-
kLuc, 1 
 
m
 
g of 
 
b
 
-actin 
 
b
 
-galactosidase (
 
b
 
-gal), and various
amounts of expression plasmids by the calcium phosphate copre-
cipitation method. Total amounts of DNA were adjusted with
empty vector at 10 
 
m
 
g. The cells were stimulated with anti-
CD40 mAb 24 h after transfection. The cells were lysed in Pi-
caGene
 
TM
 
 Cell Culture Lysis Reagent LC
 
b
 
 (Toyo Ink, Tokyo,
Japan) 24 h after incubation, and luciferase activity was measured
by use of a luciferase assay kit, PicaGene
 
TM
 
 (Toyo Ink), followed
by normalization of transfection efficiency by 
 
b
 
-gal activity.
 
Results and Discussion
 
TRAF6 Is a Signal Transducer of Both ERK and NF
 
k
 
B
Activation.
 
Overexpression of TRAF2, TRAF5, and TRAF6
results in its aggregation and causes activation of the NF
 
k
 
B 
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signaling pathway, which could be similar to that induced
by ligand-triggered receptor aggregation (6, 8, 9, 30, 33).
Therefore, to investigate which TRAF proteins might par-
ticipate in ERK activation, we cotransfected human em-
bryonic kidney 293 cells with various TRAF expression
vectors and an GST-ERK2 fusion construct. After transfec-
tion, the GST–ERK2 fusion protein was precipitated by use
of glutatione Sepharose 4B from the cell lysate, and the
ERK activity was analyzed by an in vitro kinase assay, with
myelin basic protein (MBP) used as an exogenous substrate.
As shown in Fig. 1 
 
A
 
, transient expression of full-length
TRAF6, but not TRAF2, TRAF3, or TRAF5, stimulated
exogenous ERK activity approximately fivefold above the
vector control, suggesting that transient expression of
TRAF6 stimulates ERK activity in the 293 cell line.
ERK is known to phosphorylate target protein within the
cytosol (42), whereas, under certain conditions, ERK trans-
locates to the nucleus to phosphorylate the nuclear substrate
(41, 43–45). To investigate the effect of various TRAF pro-
teins on ERK activity in the nucleus, we used an ERK-
dependent activator and reporter system, established by
Davis and coworkers (40, 41, and see Materials and Methods).
Human 293 cells were transiently transfected with various
TRAF expression vectors, together with an ERK-dependent
activator, a fusion construct of the GAL4 DNA-binding do-
main and the nuclear localization signal/NH
 
2
 
-terminal trans-
activation domain of c-Myc, and a luciferase reporter plas-
mid containing GAL4 binding sites adjacent to a thymidine
Figure 2. Inhibition of
TRAF6-mediated ERK activity
by dominant-negative mutant of
Raf and MEK1, but not by Ras.
Cells (106) were cotransfected
with ERK-dependent activator
and reporter (A) or 500 ng of
GST-ERK2 (B) and full-length
TRAF6 (5 mg), together with 5
mg of N17Ras (DN Ras), DN-
Raf, or MEK1DN ( DN MEK).
Cell lysates were prepared 48 h
after transfection and subjected
to luciferase assay (A) or in vitro
kinase assay (B). The mean value
of relative activity of ERK-
dependent luciferase reporter
(column) in four independent ex-
periments was calculated from a
mean value of a single experi-
ment in triplicate (closed circles).
Arrowhead, phosphorylated MBP
in the autoradiogram.
 
tent of stimulation in ERK and NF
 
k
 
B by transient expression of TRAF6
(5 
 
m
 
g) in 
 
B
 
 is also shown in 
 
C.
 
 The mean value of two independent ex-
periments (
 
column
 
) was calculated from a mean value of a single experi-
ment in triplicate (
 
closed circles
 
).
 
Figure 1.
 
Transient expression of TRAF6-stimulated ERK activity in
293 cells. (
 
A
 
) Cells (10
 
6
 
) were transiently transfected with expression plas-
mid of TRAF proteins (5 
 
m
 
g each) together with GST-ERK2. GST-
ERK2 fusion protein was precipitated by use of glutathione Sepharose 4B
from cell lysates 48 h after transfection and subjected to in vitro kinase as-
say using MBP as a substrate. 
 
Arrow
 
, phosphorylated MBP in the autora-
diogram. (
 
B
 
) Cells (10
 
6
 
) were transiently transfected with 100 ng of ERK-
dependent activator pGAL4MycN and 500 ng of the reporter pGAL4tkLuc
(
 
a
 
) or 20 ng of the NF
 
k
 
B-dependent luciferase reporter pkBtkLuc (
 
b
 
), to-
gether with empty vector, full-length TRAF6 (3 or 5 
 
m
 
g), or the TRAF-C
of TRAF6 (3 or 5 
 
m
 
g). Total amount of DNA was adjusted with empty
vector at 10 
 
m
 
g. Luciferase activities were measured 48 h after transfection
and normalized by b-gal expression. The extent of stimulation (relative
activation) was calculated by comparison between luciferase activity given
by the cells cotransfected with each TRAF expression plasmid and that of
cells transfected with empty vector. (C) Cells (106) were transiently
cotransfected with either TRAF2, TRAF3, or TRAF5 (5 mg each) and
ERK– (a) or NFkB–dependent luciferase reporter (b). Cell lysates were
subjected to luciferase assay 48 h after transfection. The results shown in B
and C were obtained from parallel experiments. For comparison, the ex-240 TRAF6 Stimulates ERK Activity in CD40 Signaling
kinase promoter, as an ERK-dependent reporter (40, 41). In
addition, to confirm the activity of TRAF proteins, we
cotransfected 293 cells with various TRAF expression vec-
tors and the NFkB-dependent luciferase reporter.
As shown in Fig. 1 B a, transient expression of full-length
TRAF6 triggered activation of the cotransfected ERK-
dependent reporter in a dose-dependent manner to a max-
imum of approximately fourfold above the vector control,
whereas a deletion of the RING finger and zinc fingers of
TRAF6 (TRAF-C) abolished the activity of ERK activation.
Consistent with previous reports (9, 33), transient expres-
sion of full-length TRAF6, but not TRAF-C of TRAF6,
caused NFkB activation in the 293 cell line (Fig. 1 B b),
suggesting that TRAF6 stimulates both ERK and NFkB
activity through its NH2-terminal region containing the
RING finger and zinc fingers. Parallel experiments showed
that transient expression of full-length TRAF2 and TRAF5
had no effect on ERK activity, whereas it stimulated NFkB
activity efficiently (Fig. 1 C; 6, 8, 30–32). In this context,
previous reports also ruled out the role of TRAF2 in ERK
activation (34, 36). Transient expression of TRAF3 stimu-
lated neither ERK nor NFkB activity, in agreement with
previous reports (7, 9, 34). Taken together, these results
suggest that TRAF6, but not TRAF2, TRAF3, or TRAF5, is
a transducer of both ERK and NFkB activation.
TRAF6 Stimulates ERK That Is Largely Independent of
Ras. The Ras-dependent protein kinase cascade leading
from various receptors to ERK is dependent on the protein
kinase Raf-1, which activates a dual-specificity kinase, MEK
(42). To investigate the role of Ras, Raf-1, and MEK1 in
TRAF6-mediated ERK activation, we cotransfected 293
cells with a full-length TRAF6 and ERK-dependent acti-
vator and reporter, or GST-ERK, together with a dominant-
negative mutant of H-Ras (N17Ras; 38), c-Raf-1, which
contains only the NH2-terminal regulatory domain (DN-
Raf; 37), or MEK1, in which Asp208 was replaced with Ala
(MEK1DN; 39). Some experiments were performed in par-
allel with the experiments depicted in Fig. 4. As shown in
Fig. 2, coexpression of N17Ras had no effect on the activity
of the cotransfected ERK-dependent reporter (Fig. 2 A) or
on the exogenous ERK kinase activity (Fig. 2 B), which were
increased five- to sixfold above the vector control by tran-
sient expression of TRAF6. The results suggest that TRAF6
may stimulate ERK activity along a Ras-independent path-
way.
The dominant-negative DNRaf and MEK1DN suppressed
TRAF6-mediated ERK activity in the 293 cell line, but
not entirely (Fig. 2, A and B). Although ERK activation is
essentially induced by growth factors via a Ras-mediated
pathway (42), the result could be interpreted as evidence
that the diversified signal cascades regulate ERK activity,
sometimes in a cell-type–specific manner, via c-Raf-1 and
other possible MAPK kinase kinase in a Ras-independent
fashion (46–51).
TRAF6 Is Involved in ERK Activation in CD40 Signaling.
The truncated mutant of TRAF proteins that lack the
RING finger or the RING finger and zinc fingers acts as a
transdominant-negative mutant to suppress NFkB activa-
tion in signaling through TNFR1, TNFR2, IL-1R, CD30,
and CD40 receptor (6, 8, 9, 28, 30, 31, 33), in which the
dominant-negative mutant may act specifically by replacing
the corresponding endogenous wild-type TRAF protein.
To investigate whether TRAF6 could be involved in
ERK activation by CD40, we cotransfected 293 cells with
the TRAF-C of TRAF6 and ERK-dependent activator
and reporter, or GST-ERK, together with full-length CD40
cDNA. Because a previous report suggested that the NH2-
terminal CD40 cytoplasmic tail at positions 210–225 could
be essential for TRAF6 binding and could function for
NFkB activation (9), the involvement of TRAF6 in ERK
activation by CD40 was also investigated by transient trans-
fection of the TRAF-C of TRAF6 and ERK-dependent
activator and reporter, or GST-ERK, into 293 cells coex-
pressing a deletion mutant of CD40, CD40D246 (9), that
removes the COOH-terminal cytoplasmic tail at positions
226–257. Previous results showed that TRAF6 interacts
with the CD40D246 construct in vivo (9).
As shown in Fig. 3, A and B, cross-linking of full-length
CD40 and CD40D246 caused ERK activation approxi-
mately four- to sixfold above the level of unstimulated
cells, comparable to the magnitude of the endogenous
ERK activity that was transiently increased in 293 transfec-
tants which constitutively expressed CD40 after stimulation
with anti-CD40 mAb (data not shown). As shown in Fig.
3, A (a) and B both ERK-dependent reporter activity (Fig.
3 A) and the exogenous ERK kinase activity (Fig. 3 B) me-
diated by full-length CD40 were suppressed by coexpres-
sion of TRAF-C of TRAF6 in a dose-dependent manner
to a maximum of 30–35% of inhibition, compatible with
the notion that TRAF6-dependent and -independent path-
ways could be involved in ERK activation by CD40 (see
below). Coexpression of the TRAF-C of TRAF6 caused
prominent suppression of ERK activity mediated by cross-
linking of CD40D246 in a dose-dependent manner, sug-
gesting a major role of TRAF6 in ERK activation by
CD40D246. It is not likely that the transdominant-negative
mutant of TRAF6 nonspecifically diminished the activity
of the ERK-dependent activator and reporter, because ac-
tivation of the ERK-dependent reporter mediated by co-
expression of catalytically active MEK1 (39) in the 293 cell
line was not prevented by coexpression of TRAF-C of
TRAF6 (data not shown).
In control experiments, transient expression of the
TRAF-C of TRAF6 caused prominent suppression of the
activity of cotransfected NFkB-dependent reporter medi-
ated by CD40D246 in the 293 cell line (Fig. 3 C b), consis-
tent with previous reports (9). In contrast to ERK activa-
tion, the activation of NFkB activity by full-length CD40
was greater than that by CD40D246, and z50% of the ac-
tivity was suppressed by coexpression of the TRAF-C of
TRAF6 (Fig. 3 C a). Because of a similar frequency and the
level of expression of full-length CD40 and CD40D246 in
the 293 cell line in transient transfection assays (data not
shown), the results seem compatible with the notion that
distinct regions of the CD40 cytoplasmic domain could be
required for full activation of NFkB in the 293 cell line.241 Kashiwada et al.
Figure 3. Transient expression of TRAF-C of TRAF6 caused inhibi-
tion of ERK and NFkB activity mediated by cross-linking of CD40.
Cells (106) were transiently cotransfected with ERK-dependent activator
and reporter (A), GST-ERK2 fusion construct (B), or NFkB-dependent
reporter (C) and either l mg of full-length CD40 (a) or CD40D246 (b),
together with 1, 3, or 5 mg of TRAF-C domain of TRAF6. Total
amount of DNA was adjusted with empty vector at 10 mg. Cells were
stimulated with anti-CD40 mAb 24 h after transfection. After 24 h of in-
cubation, ERK activity was measured by luciferase assay (A) or in vitro
kinase assay (B). Arrowhead, phosphorylated MBP in the autoradiogram is
indicated by an arrowhead. NFkB activity was measured by luciferase as-
say (C). Relative activation of ERK and NFkB in 293 cells at each trans-
fection was calculated as described above. The mean value of two inde-
pendent experiments (column) was calculated from a mean value of a single
experiment in triplicate (closed circles).
Figure 4. ERK activation by cross-linking of full-length, but not that
by CD40D246, was prominently suppressed by dominant negative mutant of
Ras. Cells (106) were cotransfected with ERK– (A) or NFkB–dependent
reporter (B) and either 1 mg of full-length CD40 (a) or CD40D246 (b),
together with 5 mg of N17Ras, DNRaf, and MEKDN. Total amount of
DNA was adjusted with empty vector at 10 mg. Cells were stimulated
with anti-CD40 mAb 24 h after transfection. After 24 h incubation, cell
lysates were subjected to luciferase assay. Relative activation of ERK and
NFkB in each transfection was calculated as described above. The mean
value of two to three independent experiments (column) was calculated
from a mean value of a single experiment in triplicate (closed circle).242 TRAF6 Stimulates ERK Activity in CD40 Signaling
CD40 Activates ERK by the Ras-dependent Pathway and
Ras-independent Pathway in which TRAF6 Could Be Involved.
To investigate the role of Ras, Raf-1, and MEK in ERK
activation by CD40, we cotransfected 293 cells with the
ERK-dependent activator and reporter, or NFkB-depen-
dent reporter as a control, and with N17Ras, DNRaf, or
MEK1DN, together with either full-length CD40 or
CD40D246. The experiments were performed in parallel
with some of the experiments depicted in Fig. 2 A. Co-
transfection of N17Ras, DNRaf, and MEK1DN caused z70%
inhibition of ERK activity mediated by cross-linking of full-
length CD40 (Fig. 4 A a). In contrast, coexpression of
N17Ras and MEK1DN did not affect NFkB activation by
both full-length CD40 and CD40D246, whereas DNRaf
marginally suppressed NFkB activation (Fig. 4 B). In con-
junction with the previous observation indicating activa-
tion of the Ras-mediated pathway by CD40 stimulation in
B cells (52), the results support the possibility that the Ras-
Raf-MEK–mediated pathway could be involved in ERK
activation, but not NFkB, by cross-linking of CD40. Tran-
sient expression of N17Ras resulted in z30% inhibition of
ERK activity mediated by CD40D246, compatible with
the notion that TRAF6 is a major transducer of ERK acti-
vation by CD40D246, whose activity is mediated by a Ras-
independent pathway.
Taken together, these results support the possibility that
CD40 may activate ERK via Ras-dependent and -inde-
pendent pathways in which TRAF6 could be involved. The
inhibition by a dominant-negative mutant of MEK1 in ERK
activity by full-length CD40 was more prominent than in
ERK activity mediated by TRAF6 and by CD40D246, in
which TRAF6 may play a major role. Because the MEK
isoforms MEK1 and MEK2 are an ERK-specific kinase (53),
these results might imply that preferential usage of MEK
isoforms would differ in TRAF6-dependent and -indepen-
dent pathways in CD40 signaling. In this context, it has
been suggested that the signaling pathways leading to acti-
vation of MEK isoforms appear to differ, and that each
MEK isoform could be preferentially used in a particular
external stimulus in a certain type of cell (54–56). Further
study is needed to clarify the signaling pathway coupling
TRAF6 to ERK activation.
Given that full ERK activity is stimulated through
TRAF6-dependent and -independent pathways in CD40
signaling, a similar extent of ERK activation by full-length
CD40 and CD40D246 in the 293 cell line led to the idea
that ERK activity could be regulated in full-length CD40
signaling in 293 cells, probably via activation of MAPK
phosphatase or downregulation of MEK activity (57–60).
In contrast to ERK activation in murine splenic resting B
cells (17, 18), it was reported that CD40 stimulation did
not cause ERK activation in human tonsil B cells (15, 16).
Whether ERK activation is regulated in CD40 signaling,
depending on the maturation stage of B cells, would be
worth analyzing.
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